NEWS - Dec 28, 2015 Relmada Therapeutics Recommends Stockholders Vote "FOR" Relmada's Director Nominees on the WHITE Proxy Card Today Read more
NEWS - Dec 23, 2015 U.S. Federal Court Grants Preliminary Injunction Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern Read more
NEWS - Dec 21, 2015 Relmada Sends Letter To Stockholders Highlighting Significant Progress In Value Creation Strategy Overseen By Board And Management Team Read more
NEWS - Dec 15, 2015 Leading Independent Proxy Advisory Firm Glass Lewis Recommends Relmada Stockholders Vote the WHITE Proxy Card "FOR" Relmada's Director Nominees: Shreeram Agharkar and Maged Shenouda Read more
NEWS - Dec 14, 2015 Pharmaceutical Industry Leader James Dolan Joins Relmada Therapeutics Advisory Team Read more
NEWS - Dec 11, 2015 U.S. Federal Court Issues Temporary Restraining Order Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern Read more
NEWS - Dec 10, 2015 Relmada Therapeutics Announces Additional Information Regarding Positive Topline Results for Proof-of-Concept Study with BuTab Read more
NEWS - Dec 9, 2015 Relmada Therapeutics Announces Positive Topline Results for Proof-of-Concept Study with BuTab Read more
NEWS - Dec 9, 2015 Relmada Therapeutics Files Federal Lawsuit Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern to Protect Interests of Relmada Stockholders Read more
NEWS - Dec 7, 2015 Relmada Therapeutics to Mail Letter to Stockholders Highlighting Laidlaw & Company's Questionable Business Practices and Conduct Read more
